CRISPR/Cas9-Mediated Mir-29B Editing As a Treatment of Different Types of Muscle Atrophy in Mice

Jin Li,Lijun Wang,Xuejiao Hua,Haifei Tang,Rui Chen,Tingting Yang,Saumya Das,Junjie Xiao

DOI: https://doi.org/10.1016/j.ymthe.2020.03.005

IF: 12.91

2020-01-01

Molecular Therapy

Abstract:Muscle atrophy is the loss of skeletal muscle mass and strength in response to diverse catabolic stimuli. At present, no effective treatments except exercise have been shown to reduce muscle atrophy clinically. Here, we report that CRISPR/Cas9-mediated genome editing through local injection into gastrocnemius muscles or tibialis anterior muscle efficiently targets the biogenesis processing sites in pre-miR-29b. In vivo, this CRISPR-based treatment prevented the muscle atrophy induced by angiotensin II (AngII), immobilization, and denervation via activation of the AKT-FOXO3A-mTOR signaling pathway and protected against AngII-induced myocyte apoptosis in mice, leading to significantly increased exercise capacity. Our work establishes CRISPR/Cas9-based gene targeting on miRNA as a potential durable therapy for the treatment of muscle atrophy and expands the strategies available interrogating miRNA function in vivo.